Qualitative changes in human γ-secretase underlie familial Alzheimer's disease

Presenilin (PSEN) pathogenic mutations cause familial Alzheimer's disease (AD [FAD]) in an autosomal-dominant manner. The extent to which the healthy and diseased alleles influence each other to cause neurodegeneration remains unclear. In this study, we assessed γ-secretase activity in brain sa...

Descripción completa

Detalles Bibliográficos
Autores: Szaruga, Maria, Veugelen, Sarah, Benurwar, Manasi, Lismont, S., Sepulveda-Falla, Diego, Lleó, Alberto|||0000-0002-2568-5478, Ryan, Natalie S., Lashley, Tammaryn, Fox, Nick C.|||0000-0002-6660-657X, Murayama, Shigeo, Gijsen, Harrie, De Strooper, Bart, Chávez-Gutiérrez, Lucía
Tipo de recurso: artículo
Fecha de publicación:2015
País:España
Institución:Universitat Autònoma de Barcelona
Repositorio:Dipòsit Digital de Documents de la UAB
Idioma:inglés
OAI Identifier:oai:ddd.uab.cat:300272
Acceso en línea:https://ddd.uab.cat/record/300272
https://dx.doi.org/urn:doi:10.1084/jem.20150892
Access Level:acceso abierto
Palabra clave:Adult
Aged
Alzheimer Disease
Amyloid
Amyloid beta-Protein Precursor
Amyloid Precursor Protein Secretases
Animals
Blotting, Western
Brain
Carboxypeptidases
Cells, Cultured
Female
Humans
Male
Mice, Knockout
Middle Aged
Mutation
Presenilin-1
Descripción
Sumario:Presenilin (PSEN) pathogenic mutations cause familial Alzheimer's disease (AD [FAD]) in an autosomal-dominant manner. The extent to which the healthy and diseased alleles influence each other to cause neurodegeneration remains unclear. In this study, we assessed γ-secretase activity in brain samples from 15 nondemented subjects, 22 FAD patients harboring nine different mutations in PSEN1, and 11 sporadic AD (SAD) patients. FAD and control brain samples had similar overall γ-secretase activity levels, and therefore, loss of overall (endopeptidase) γ-secretase function cannot be an essential part of the pathogenic mechanism. In contrast, impaired carboxypeptidase-like activity (γ-secretase dysfunction) is a constant feature in all FAD brains. Significantly, we demonstrate that pharmacological activation of the carboxypeptidase-like γ-secretase activity with γ-secretase modulators alleviates the mutant PSEN pathogenic effects. Most SAD cases display normal endo- and carboxypeptidase- like γ-secretase activities. However and interestingly, a few SAD patient samples display γ-secretase dysfunction, suggesting that γ-secretase may play a role in some SAD cases. In conclusion, our study highlights qualitative shifts in amyloid-β (Aβ) profiles as the common denominator in FAD and supports a model in which the healthy allele contributes with normal Aβ products and the diseased allele generates longer aggregation-prone peptides that act as seeds inducing toxic amyloid conformations.